An interventional study of endoscopic biopsy and samples of the oral cavity in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France — 2 open to participants now, 2 under way, none of them phase 3. Inflammatory Bowel Diseases · Central Hospital, Nancy, France.
Among the 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France, this one is the only one that started in 2019, is one of 2 with no phase, and was the 3rd registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →2 of the 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2019.
This study's planned enrollment of 1,000 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 601 across the 2 interventional studies, 107 across the 8 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
1 of the studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05456893Central Hospital, Nancy, FranceA Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies | 2027-09-09 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Interventional study of a group of patients with an inflammatory bowel disease (IBD; Crohn's disease (CD) or ulcerative colitis (UC)) to identify predictive and prognostic biomarkers of natural history and response to biotherapies.
Percentage of primary responders who haven't lost response to biotherapies during follow-up (anti-TNF, ustekinumab, vedolizumab).
Response to treatment will be evaluated using objective criteria for measuring intestinal inflammation: endoscopic remission (endoscopic biopsy and surgical specimens), radiological (MRI), and / or biological (CRP, fecal calprotectin) .
Response to therapy rates will be correlated with genomic, epigenomic, and microbiota data stratified by major environmental factors (nutrition, tobacco, physical activity).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant women, breastfeeding women
-- Age \< 18 years
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients with an established Crohn's disease or ulcerative colitis
Procedure: endoscopic biopsy · Procedure: samples of the oral cavity · Procedure: Samples of the resected specimen
Per-endoscopic biopsies
7 samples of the oral cavity with a swab
if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
Proportion of patients who have lost response to biotherapies (anti-TNF, ustekinumab, vedolizumab).
Time frame: 5 years
Proportion of patients who underwent surgery
Time frame: 5 years
Post-operative morbidity rates in IBD
Time frame: 5 years
Surgical recurrent rate in Crohn's disease
Time frame: 5 years
Proportion of patients with a destruction of the intestinal wall in CD (abscess, fistula)
Time frame: 5 years
Proportion of patients developing a cancer
Time frame: 5 years
Readmission rates for acute severe colitis or ileitis
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2034, 180 months after the start.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 180 months is above that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →